Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Arizona
Incyte Corporation
University of Wisconsin, Madison
Massachusetts General Hospital
City of Hope Medical Center
Therapeutic Advances in Childhood Leukemia Consortium
Pfizer
OHSU Knight Cancer Institute
Beth Israel Deaconess Medical Center
Case Comprehensive Cancer Center
M.D. Anderson Cancer Center
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
Icahn School of Medicine at Mount Sinai
Case Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
Bellicum Pharmaceuticals
University of Pennsylvania
Jonsson Comprehensive Cancer Center
Case Comprehensive Cancer Center
Celgene
M.D. Anderson Cancer Center
University of Wisconsin, Madison
University of Maryland, Baltimore
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Stanford University
Wake Forest University Health Sciences
Masonic Cancer Center, University of Minnesota
California Cancer Consortium
Massachusetts General Hospital
University of Louisville
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
Alliance for Clinical Trials in Oncology
Celgene
University Health Network, Toronto
National Cancer Institute (NCI)
Indiana University
Indiana University
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
University of California, San Francisco
Washington University School of Medicine
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)